Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : Outgoing Amgen CEO May Receive $49 Million After Retirement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/23/2012 | 10:52pm CEST
   By Peter Loftus 
   Of  
 

The outgoing leader of biotechnology company Amgen Inc. (AMGN) could receive payments and deferred compensation totaling more than $49 million after he retires.

Kevin Sharer, 64, plans to step down as chief executive in May and as chairman at the end of 2012, after more than a decade at the helm of the Thousand Oaks, Calif., company. President and Chief Operating Officer Robert Bradway, 49, will succeed Sharer as CEO.

Sharer isn't the only retiring drug company CEO to be poised for hefty post-retirement payments. Johnson & Johnson (JNJ) disclosed earlier this month that the estimated value of William Weldon's pension and deferred compensation was more than $143 million. Weldon is stepping down as CEO in April but will remain chairman for an undisclosed period.

In a proxy statement filed with the Securities and Exchange Commission this week, Amgen provided details about payments and deferred compensation that Sharer could receive after retirement. The figures are estimated values as of Dec. 31, 2011, and the actual values could change by the time he retires.

One category of post-retirement payments had an estimated current value of $26.9 million as of Dec. 31. These include: $6.6 million in accelerated unvested stock options; $7.8 million in accelerated unvested restricted stock units; and $12.6 million for the value of performance units for the years 2010 to 2013.

Restricted stock units are convertible into Amgen shares upon vesting, while performance units are rights to receive shares based on pre-established performance goals achieved over a period typically lasting three years.

Some of these amounts were calculated using the closing price of Amgen shares on Dec. 31, of $64.21. The stock ended Friday's trading up 4 cents at $66.66.

In addition, Sharer will be able to collect deferred compensation that had an aggregate balance of $22.5 million as of Dec. 31. This includes contributions to his retirement plan and portions of compensation from previous years that Sharer was permitted to defer.

Amgen spokeswoman Christine Regan noted that the $22.5 million balance included money Sharer had previously earned, as well as contributions from a company retirement program that is available to all regular U.S. Amgen employees.

Sharer won't be paid severance upon retirement, Regan said. Sharer will continue to collect his salary through the end of May and is entitled to a prorated portion of his 2012 bonus.

For 2011, Sharer's total compensation was valued at $18.9 million, down 11% from the $21.1 million value of his compensation for 2010 mainly because of a decline in the value of option awards.

Elements of Sharer's 2011 compensation included: $1.8 million in base salary, $9 million in stock awards, $2.4 million in option awards and $4.9 million in non-equity incentive plan compensation.

Amgen's incoming CEO Bradway received compensation valued at $7.1 million for 2011, down from $7.8 million for 2010.

This month, the compensation committee of Amgen's board approved a 36% increase in Bradway's base salary to $1.4 million in connection with his promotion to CEO.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
03/28 AMGEN : Awards Three Golden Tickets for LabCentral Residency
03/28 AMGEN : announces layoffs and relocations in Thousand Oaks
03/24 AMGEN, INC. (NASDAQ : AMGN) Amgevita Approved By The European Commission Giving ..
03/23 AMGEN : European Commission Approves AMGEVITA(TM) (Biosimilar Adalimumab) For Th..
03/21 AMGEN INC. : (AMGN) Sank To A 1-Month Low After Repatha Study
03/20 ESPERION THERAPEUTICS INC (NASDAQ : ESPR): Get It While It’s Cheap
03/19 AMGEN : Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Sig..
03/18 AMGEN : Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect ..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17 Amgen and AXT slump while Adobe and Tiffany advance
More news
Sector news : Bio Therapeutic Drugs
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
03/14 AstraZeneca ovarian cancer drug slows disease markedly in study
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/28 Akcea Therapeutics Files For $100 Million IPO
03/27 My Favorite Biotech Takeover Play
03/27 Amgen shakes up R&D staff, 400 jobs to be cut/relocated
03/27 Karyopharm's Selinexor Should Drive Substantial Growth
03/27 AMGEN : A Compelling Price On The Latest Dip
Advertisement
Financials ($)
Sales 2017 23 012 M
EBIT 2017 11 705 M
Net income 2017 8 097 M
Finance 2017 1 921 M
Yield 2017 2,74%
P/E ratio 2017 15,07
P/E ratio 2018 14,57
EV / Sales 2017 5,19x
EV / Sales 2018 4,59x
Capitalization 121 448 M
More Financials
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 186 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.12.79%121 448
CELGENE CORPORATION7.87%97 137
GILEAD SCIENCES, INC.-5.74%88 227
REGENERON PHARMACEUTIC..4.52%40 701
ACTELION LTD24.40%29 848
VERTEX PHARMACEUTICALS..23.25%22 558
More Results